Pharmaceutical News

RSS

UCSF's new pharmacy to focus on direct patient care

Although it won't be obvious to UCSF Medical Center patients, behind the scenes a family of giant robots now counts and processes their medications. With a new automated hospital pharmacy, believed to be the nation's most comprehensive, UCSF is using robotic technology and electronics to prepare and track medications with the goal of improving patient safety.

8 Mar 2011

Ambry, RainDance enter new collaboration to develop and commercialize ADME screening

RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion genetic screening panel for use on next-generation sequencing systems.

8 Mar 2011

New Lupus drug marching towards approval

A new drug for lupus from the Human Genome Sciences Inc is all set to get clearance in the US this week. If all goes through, this drug will offer patients the first approved treatment option in a half-century, setting the manufacturer up for huge sales.

7 Mar 2011

FDA says no cause for alarm on vaccines for meningitis and pneumonia

According to US health officials there are no reports that arouse new safety concerns over two children’s vaccines that have been suspended in Japan following the deaths of four babies.

7 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

7 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

Launch Excellence Services provides solutions to new pharma product market entry

The pressure for a new product to succeed at launch has never been greater with organizations across the pharmaceutical sector facing pipeline deficits, patent expirations and increasing development costs.

7 Mar 2011

FDA's action impacts Elite pharma drugs

Elite Pharmaceuticals, Inc. advises that the US Food and Drug Administration announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market.

7 Mar 2011

New research: Rectal specific microbicides can protect against HIV

Microbicides can be used to protect against HIV, and other sexually transmitted diseases, either on their own or with the added protection of a condom. New research published by BioMed Central's open access journal AIDS Research and Therapy has investigated the use of lubricants, originally designed for vaginal application, and has developed and tested new, rectal specific, formulations.

6 Mar 2011

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

Deal Search Online: Pharma is the single most active sector in decade's health care M&A market

According to Deal Search Online, an Irving Levin Associates M&A database, there has been a total of 1,431 pharmaceutical M&A deals, totaling $632.3 billion dollars committed to the industry during the ten-year period ended December 31, 2010.

5 Mar 2011

New turf battle: Retail pharmacists vs. mail order companies

The New York Times: Pharmacists Fight The Rise Of Mail Order

5 Mar 2011

FDA accepts Lundbeck's clobazam NDA for review

Lundbeck Inc. today announced the U.S. Food and Drug Administration has accepted for review a New Drug Application for the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome in patients two years and older.

5 Mar 2011

ADM, Burcon NutraScience enter license agreement to market CLARISOY soy protein

Burcon NutraScience Corporation announced today that the company has entered into a license agreement with Archer Daniels Midland Company for the worldwide production, distribution and sale of Burcon's CLARISOY soy protein.

5 Mar 2011

Grifols receives FDA approval for Alphanate to treat vCJD

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration for revised labeling for Alphanate Antihemophilic Factor/von Willebrand Factor Complex indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob Disease.

5 Mar 2011

Scientific symposium to examine new approaches to schizophrenia drug development

Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.

5 Mar 2011

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative.

5 Mar 2011

Football player announces release of new pre-workout intensity supplement

Ray Lewis, one of the greatest players ever to step on a football field, today announced the release of an all new pre-workout intensity supplement, called Power Fuel, which will feature Lewis on its packaging and contain a powerful custom ingredient blend named in his honor.

5 Mar 2011

Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

The U.S. Food and Drug Administration today announced that monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH).

5 Mar 2011

Pharmaceutical News

UCSF's new pharmacy to focus on direct patient care

Ambry, RainDance enter new collaboration to develop and commercialize ADME screening

New Lupus drug marching towards approval

FDA says no cause for alarm on vaccines for meningitis and pneumonia

5a-reductase inhibitors for male health problems can affect sexual health

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

Launch Excellence Services provides solutions to new pharma product market entry

FDA's action impacts Elite pharma drugs

New research: Rectal specific microbicides can protect against HIV

FDA approves change to prescribing information for Gilead Sciences' Letairis

Deal Search Online: Pharma is the single most active sector in decade's health care M&A market

New turf battle: Retail pharmacists vs. mail order companies

FDA accepts Lundbeck's clobazam NDA for review

ADM, Burcon NutraScience enter license agreement to market CLARISOY soy protein

Grifols receives FDA approval for Alphanate to treat vCJD

Scientific symposium to examine new approaches to schizophrenia drug development

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Football player announces release of new pre-workout intensity supplement

Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News